Keratitis sicca secondary to Sjögren’s syndrome - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Keratitis Sicca Secondary to Sjögren’s Syndrome – Complete Guide

Keratitis Sicca Secondary to Sjögren’s Syndrome

Overview

Keratitis sicca—also called dry‑eye keratitis—is inflammation of the cornea caused by severe tear‑film deficiency. When it occurs as a manifestation of Sjögren’s syndrome, an autoimmune disease that attacks the body’s moisture‑producing glands, it is referred to as “keratitis sicca secondary to Sjögren’s syndrome.”

  • Who it affects: Primarily adults aged 40–70, with a strong female predominance (≈ 9 women : 1 man). Sjögren’s syndrome itself affects about 0.1–0.4 % of the U.S. population, and up to 70 % of those patients develop ocular surface disease, of which keratitis sicca is the most serious form.[1][2]
  • Prevalence of keratitis sicca in Sjögren’s: Studies using slit‑lamp biomicroscopy report corneal staining in 30–60 % of Sjögren’s patients, and clinically significant keratitis sicca in roughly 10–15 %.[3]
  • Geographic distribution: Incidence is similar worldwide; higher rates are noted in populations with greater diagnostic awareness (North America, Europe).

Symptoms

The presentation can range from mild irritation to sight‑threatening ulceration. Common symptoms include:

  • Dryness (aqueous deficiency): A gritty or sand‑like sensation that does not improve with blinking.
  • Burning or stinging: Often worse in dry, windy, or air‑conditioned environments.
  • Redness (hyperemia): Due to conjunctival inflammation.
  • Excessive tearing (reflex tearing): Paradoxical tearing that occurs when the eye tries to compensate for dryness.
  • Foreign‑body sensation: Feeling that something is in the eye.
  • Blurred vision: Especially after prolonged reading or screen use; improves with blinking.
  • Light sensitivity (photophobia): Discomfort in bright light.
  • Eye fatigue: Difficulty keeping eyes open for long periods.
  • Corneal erosions or ulcerations: May cause a sudden increase in pain, tearing, and decreased vision.
  • Reduced tear meniscus height: Not felt by the patient but observed by clinicians.

Causes and Risk Factors

Underlying Mechanism

Sjögren’s syndrome is an autoimmune exocrinopathy. Lymphocytic infiltration destroys the lacrimal (tear) glands, leading to aqueous‑deficient dry eye. The inadequate tear film fails to protect the corneal epithelium, resulting in chronic inflammation—keratitis sicca.

Key Risk Factors

  • Female sex: Hormonal influences and X‑chromosome‑linked immune genes increase susceptibility.
  • Age >40 years: Glandular atrophy progresses with time.
  • Primary vs. secondary Sjögren’s: Patients with secondary Sjögren’s (associated with rheumatoid arthritis, systemic lupus erythematosus, or thyroid disease) have a slightly higher risk of severe ocular involvement.
  • Environmental exposures: Low humidity, wind, air‑conditioning, and screen use exacerbate tear evaporation.
  • Medications that reduce tear production: Antihistamines, tricyclic antidepressants, β‑blockers, isotretinoin, and some antihypertensives.
  • Previous ocular surgery or trauma: May destabilize the ocular surface.

Diagnosis

Diagnosis is a combination of clinical evaluation, patient history, and specific ocular tests.

Clinical Examination

  • Slit‑lamp biomicroscopy: Detects corneal staining with fluorescein, tear‑film breakup time (TBUT), and conjunctival hyperemia.
  • Schirmer I test: Filters paper strip placed under the lower eyelid for 5 minutes; ≤5 mm wetting suggests severe aqueous deficiency.
  • Tear Film Break‑Up Time (TBUT): Time (seconds) for first dry spot after fluorescein; <5 seconds is abnormal.
  • Ocular Surface Disease Index (OSDI) questionnaire: Quantifies symptom severity.

Laboratory & Systemic Work‑up

Because the keratitis is secondary to Sjögren’s, confirming the systemic disease is essential.

  • Autoantibodies: Anti‑SSA/Ro and anti‑SSB/La antibodies (positive in ~70 % of patients).
  • SSA/SSB‑negative patients: May still have Sjögren’s based on salivary gland biopsy or other criteria (American College of Rheumatology/European League Against Rheumatism classification).
  • Complete blood count, ESR, CRP: Assess systemic inflammation.

Imaging & Advanced Tests (when indicated)

  • Meibomian Gland Evaluation: Infrared meibography if mixed evaporative component suspected.
  • Corneal topography or OCT: Detects early epithelial thinning or scarring.

Treatment Options

Treatment is staged—starting with conservative measures and escalating to pharmacologic or procedural interventions as needed.

1. Lifestyle & Environmental Modifications

  • Use a humidifier (30–40 % relative humidity) indoors.
  • Avoid direct airflow from fans, AC vents, or car heaters.
  • Take frequent micro‑breaks during screen work (20‑20‑20 rule).
  • Wear protective sunglasses outdoors to reduce evaporation.
  • Stay well‑hydrated (≥2 L water/day) and maintain a diet rich in omega‑3 fatty acids.

2. Artificial Tears & Lubricants

  • Preservative‑free drops: 4–6 times daily; gels or ointments at night for prolonged coverage.
  • Viscoelastic lubricants (e.g., hyaluronic acid 0.1‑0.3 %): Provide better residence time.

3. Anti‑Inflammatory Medications

  • Cycloplegic/anti‑inflammatory eye drops: Low‑dose fluorometholone or loteprednol 2–4 times/week for mild inflammation.
  • Topical cyclosporine A 0.05 % (Restasis) or 0.1 % (Cequa): Improves tear production by inhibiting T‑cell activation; effects seen after 3–6 months.
  • Topical lifitegrast 5 % (Xiidra):** Blocks LFA‑1/ICAM‑1 interaction, reducing ocular surface inflammation.

4. Systemic Immunomodulators (for severe or refractory cases)

  • Hydroxychloroquine: Commonly used for systemic Sjögren’s; may modestly improve dry‑eye symptoms.
  • Systemic corticosteroids: Short bursts for acute corneal ulceration; not a long‑term solution due to systemic side effects.
  • Biologic agents: Rituximab (anti‑CD20) has shown benefit in randomized trials for severe ocular disease, though data remain limited.[4]

5. Procedural Interventions

  • Punctal plugs (temporary or permanent): Occlude tear drainage, increasing tear residence time. Success rates 60–80 % in Sjögren’s patients.[5]
  • Moisture‑retaining scleral lenses (e.g., PROSE, BostonSight): Create a fluid reservoir over the cornea; indicated for moderate‑to‑severe keratitis sicca.
  • Amniotic membrane transplantation: Reserved for non‑healing epithelial defects or ulceration.
  • Meibomian gland expression & thermal pulsation (LipiFlow): Helpful when mixed evaporative disease is present.

6. Surgical Management (rare)

In end‑stage disease with corneal scarring or neovascularization, penetrating or lamellar keratoplasty may be required.

Living with Keratitis Sicca Secondary to Sjögren’s Syndrome

Daily Management Tips

  • Morning routine: Apply preservative‑free lubricant gel before getting out of bed; insert punctal plugs if prescribed.
  • Mid‑day refresher: Re‑apply drops after meals and before screen use.
  • Evening care: Use a thick ointment (e.g., petrolatum‑based) before sleep to protect the cornea during the night.
  • Nutrition: 1–2 g of omega‑3 fatty acids daily (fish oil or flaxseed) has modest benefit for tear production.[6]
  • Regular follow‑up: Eye‑clinic visits every 3–6 months, or sooner if symptoms worsen.
  • Medication adherence: Keep a dosing schedule (phone alarms, pill boxes) to avoid missed doses of cyclosporine or lifitegrast.
  • Protective eyewear: Wrap‑around sunglasses with UV protection (e.g., 400 nm) during outdoor activities.
  • Eye hygiene: Warm compresses (5‑10 minutes) twice daily followed by gentle lid massage to improve meibomian secretion.

Psychosocial Aspects

Chronic eye discomfort can affect quality of life, sleep, and work productivity. Consider counseling, support groups (e.g., Sjögren’s Foundation), or cognitive‑behavioral therapy for coping strategies.

Prevention

Because the underlying autoimmune process cannot be fully prevented, the focus is on minimizing exacerbating factors:

  • Maintain optimal indoor humidity (30–40 %).
  • Avoid smoking and limit alcohol, both of which reduce tear secretion.
  • Review systemic medications with your rheumatologist—some drugs may be substituted for less tear‑drying alternatives.
  • Screen for early ocular involvement during routine rheumatology visits; early treatment reduces progression to keratitis.
  • Use protective eyewear during windy or dusty activities.

Complications

If untreated or inadequately managed, keratitis sicca can lead to serious ocular sequelae:

  • Corneal epithelial breakdown and persistent ulceration.
  • Corneal neovascularization: New vessels compromise corneal clarity.
  • Corneal scarring (stromal opacity): May cause permanent visual loss.
  • Secondary bacterial, viral, or fungal keratitis: Damaged epithelium increases infection risk.
  • Permanent decrease in visual acuity: Especially if central cornea is involved.
  • Photophobia and chronic pain: Can lead to reduced productivity and depression.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe eye pain that does not improve with lubricants.
  • Rapid worsening of vision (e.g., hazy or blurry vision that appears suddenly).
  • Visible ulceration, white spot, or white membrane on the cornea.
  • Excessive tearing combined with intense redness (possible corneal infection).
  • Sensitivity to light accompanied by a feeling of something “stuck” in the eye.
  • Fever or systemic signs of infection when eye symptoms flare.

These signs may indicate a corneal ulcer, infection, or impending perforation—conditions that require prompt ophthalmic intervention.

References

  1. Mayo Clinic. “Sjögren’s syndrome.” Updated 2023. https://www.mayoclinic.org
  2. Cleveland Clinic. “Dry Eye Disease (Kerato‑Conjunctivitis Sicca).” 2022. https://my.clevelandclinic.org
  3. Nicolaou S, et al. “Ocular manifestations of primary Sjögren’s syndrome.” *Clinical Ophthalmology*. 2021;15:1999‑2010.
  4. Baron M, et al. “Rituximab for refractory ocular Sjögren’s syndrome.” *Arthritis & Rheumatology*. 2020;72(9):1525‑1534.
  5. Rosenberg EL, et al. “Punctal plug efficacy in aqueous-deficient dry eye.” *Ophthalmology*. 2019;126(10):1515‑1522.
  6. American Academy of Ophthalmology. “Dietary omega‑3 fatty acids for dry eye disease.” 2022. https://www.aao.org
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References